<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="938">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711486</url>
  </required_header>
  <id_info>
    <org_study_id>ContraloidAD</org_study_id>
    <nct_id>NCT04711486</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease</brief_title>
  <official_title>A Single-centre, Randomized, Placebo-controlled, Double-blind, Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berlin Institute of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal Agency for Disruptive Innovation - SPRIN-D</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with mild cognitive impairment due to Alzheimer's disease (MCI due to AD) are at&#xD;
      high risk to develop Alzheimer´s dementia. The therapeutic agent Contraloid has the potential&#xD;
      to influence the chronic neurodegenerative process of AD. As Contraloid was so far only&#xD;
      administered to healthy subjects, the rational of the proposed study is first to collect&#xD;
      safety data in patients diagnosed with MCI due to AD, as the absorption, distribution,&#xD;
      metabolism and excretion processes may be altered by disease, aging, comorbidities and&#xD;
      concomitant drug therapies. Additionally, the design of a subsequent phase II study will be&#xD;
      based on the data of this study. The results of the exploratory analyses will enable power&#xD;
      calculations and the identification of the most useful and reliable biomarkers for the&#xD;
      subsequent proof of concept phase II study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Actual">January 13, 2022</completion_date>
  <primary_completion_date type="Actual">January 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>From baseline (day 1) to follow-up (day 56)</time_frame>
    <description>Number of Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Number of Participants with abnormal laboratory values (urinalysis, CBC, Quick, PTT, Creatinine, CK, CRP, ALT, AST)</measure>
    <time_frame>From baseline (day 1) to follow-up (day 56)</time_frame>
    <description>Laboratory values: urinalysis, CBC, Quick, PTT, Creatinine, CK, CRP, ALT, AST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Number of Participants with abnormal ECG values</measure>
    <time_frame>From baseline (day 1) to follow-up (day 56)</time_frame>
    <description>ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>pre-dose and 15 min, 1 hour, 2 hours, 4 hours post-dose at day 1 and day 28</time_frame>
    <description>Cmax in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: The time at which Cmax is observed (Tmax)</measure>
    <time_frame>pre-dose and 15 min, 1 hour, 2 hours, 4 hours post-dose at day 1 and day 28</time_frame>
    <description>Tmax in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Terminal elimination half-life (t1/2) in plasma</measure>
    <time_frame>pre-dose and 15 min, 1 hour, 2 hours, 4 hours post-dose at day 1 and day 28</time_frame>
    <description>t1/2 in plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy: Change of biomarkers in CSF</measure>
    <time_frame>Baseline to end of treatment (day 28) to follow-up (day 56)</time_frame>
    <description>Biomarkers: p-tau, t-tau, NFL, Aβ 1-40, Aβ 1-42 and Aβ and tau oligomers</description>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy: Change of biomarkers in plasma</measure>
    <time_frame>Baseline to end of treatment (day 28) to follow-up (day 56)</time_frame>
    <description>Biomarkers: p-tau, t-tau, NFL, Aβ 1-40, Aβ 1-42 and Aβ and tau oligomers</description>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy optional: Change of biomarkers in feces</measure>
    <time_frame>Baseline to end of treatment (day 28) to follow-up (day 56)</time_frame>
    <description>Biomarkers: p-tau, t-tau, NFL, Aβ 1-40, Aβ 1-42 and Aβ and tau oligomers</description>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy: Change in CERAD+ test battery scores</measure>
    <time_frame>Baseline to end of treatment (day 28) to follow-up (day 56)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy: Change in CDR-Sum of boxes</measure>
    <time_frame>Baseline to end of treatment (day 28) to follow-up (day 56)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Mild Cognitive Impairment Due to Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Contraloid acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg Contraloid/participant administered orally (for 28 days) as a single daily dose.&#xD;
Other Name: PRI-002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mg Placebo (Microcrystalline cellulose)/participant administered orally (for 28 days) as a single daily dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Contraloid acetate</intervention_name>
    <description>Oral administration of drug substance capsules</description>
    <arm_group_label>Contraloid acetate</arm_group_label>
    <other_name>PRI-002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of placebo without any exipients.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Microcrystalline cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with MCI due to AD according to DSM-V&#xD;
&#xD;
          2. Age between 50 and 80 years (male and female)&#xD;
&#xD;
          3. MMSE score 22-30&#xD;
&#xD;
          4. Written informed consent (according AMG §40 (1) 3b)&#xD;
&#xD;
          5. Level of Aβ-oligomers: mind. 1fM&#xD;
&#xD;
          6. CSF according to diagnosis (p-tau &gt; 62 pg/ml, total CSF Aβ 1-42/1-40 ratio ≤ 0.055)&#xD;
&#xD;
          7. 3 months prior to screening stable medication&#xD;
&#xD;
          8. Females without childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of seizures&#xD;
&#xD;
          2. History of stroke or TIA&#xD;
&#xD;
          3. Unstable medical, neurological or psychiatric condition&#xD;
&#xD;
          4. Current treatment with one of the following substances:&#xD;
&#xD;
               -  Typical antipsychotic or neuroleptic medication within 6 months of screening&#xD;
&#xD;
               -  Anti-coagulation medications within 3 months of screening&#xD;
&#xD;
               -  Chronic use of opiates or opioids (including long-acting opioid medication)&#xD;
                  within 3 months of screening&#xD;
&#xD;
               -  Stimulant medications (amphetamine, methylphenidate preparations, or modafinil)&#xD;
                  within 1 month of screening and throughout the study&#xD;
&#xD;
               -  Chronic use of benzodiazepines, barbiturates, or hypnotics from 3 months before&#xD;
                  screening&#xD;
&#xD;
          5. Persons who are legally detained in an official institution&#xD;
&#xD;
          6. Persons who may be dependent on the sponsor, the investigator or the trial site&#xD;
&#xD;
          7. Persons without caregiver&#xD;
&#xD;
          8. Participation in other clinical trials according to AMG (1 month before the time of&#xD;
             this trial)&#xD;
&#xD;
          9. Persons showing EEG abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charité University Medicine</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>August 22, 2022</last_update_submitted>
  <last_update_submitted_qc>August 22, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Oliver Peters, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

